Overview
Hepatocellular carcinoma (HCC) patients is a common disease in the East Asia. During the disease course, 20%-50% patients suffered portal vein tumor thrombus (PVTT), which is characterized with poor outcome and low response for treatments. Although BCLC (Barcelona clinical liver cancer) system recommend to palliative targeted treatment, the East Asian countries recommend to resection or transartery chemoembolization (TACE).
Recently, FOLFOX (Oxaliplatin and 5-fluorouracil) based hepatic artery infusion chemotherapy (HAIC) exhibited high response rate for advanced HCC.
Pilot study showed TACE combined HAIC (TACE-HAIC) had better tumor response, with low progression disease rate.
Whether TACE-HAIC would improve survival for patients with PVTT is need to further to study. A randomized clinical trial compared neo-TACE-HAIC with surgery versus surgery alone is aimed to answer this question.
Eligibility
Inclusion Criteria:
- Age 18-75 years;
- Patients with resectable primary hepatocellular carcinoma and portal vein tumor thrombus, which was not located in main portal vein;
- Child-Pugh A or B (7 score) liver function;
- With more than 3 months expected survival;
- The volume of residual liver more than 30%
Exclusion Criteria:
- Patients with primary hepatocellular carcinoma and major portal vein tumor thrombus
- With extrahepatic metastasis or unresectable HCC
- Pregnant woman or sucking period;
- With other malignant cancer;
- Received chemotherapy, target therapy or immunosuppressive drugs therapy before this study.